Astrana Health’s second quarter was marked by robust revenue expansion and strong operational execution, which was reflected in the positive market reaction following the earnings release. Management attributed the double-digit growth to sustained momentum in its Care Partners segment and a pronounced shift toward full-risk contract arrangements. CEO Brandon Sim highlighted that 78% of revenue now comes from these full-risk models, up from 60% a year ago, emphasizing the company’s focus on coordinated care and end-to-end management. Sim noted, “Our delegated model gives us real-time visibility into utilization and claims, allowing for earlier, more coordinated interventions.”

Is now the time to buy ASTH? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Astrana Health’s Q2 Earnings Call

• Hua Ha (Baird) pressed management on the outlook for Prospect Health’s integration and whether M&A activity will pause. CEO Brandon Sim answered that large-scale M&A will pause until leverage targets are met, with integration of Prospect now the top priority.
• Ryan Langston (TD Cowen) sought details on utilization trends outside California and the impact on profitability. Sim explained that most revenue is still California-based but noted that Nevada is now EBITDA positive and Texas is on track for breakeven.
• Craig Jones (Bank of America) asked about Medicaid rate trends and margin recovery. Sim acknowledged ongoing volatility and active negotiations, with conservative assumptions baked into future guidance.
• Jailendra Singh (Truist Securities) requested clarity on the cost trend outlook and potential for exchange-related utilization spikes. Sim said higher cost trends are already incorporated into guidance, and exchange exposure remains limited and manageable.
• Andrew Mok (Barclays) inquired about the company’s approach to value-based care recontracting and payer relationships. Sim emphasized Astrana’s stable partnerships and reputation for reliability during industry volatility.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will focus on (1) progress in realizing Prospect Health integration synergies and operational alignment, (2) signs that full-risk contract migration continues to drive both revenue and improved cost controls, and (3) the outcome of Medicaid contract negotiations and how the company adapts to policy-driven enrollment changes. Execution on these fronts, alongside further technology adoption in care management, will be key indicators of Astrana’s ongoing performance.

Astrana Health currently trades at $29.63, up from $21.46 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.